Financial Performance - For the fiscal year ending December 31, 2024, the company reported revenue of approximately RMB 13,663.5 million, a slight increase of 0.1% compared to RMB 13,650.2 million in 2023[3]. - The net profit for the year was approximately RMB 2,258.3 million, reflecting a growth of 2.7% from RMB 2,199.1 million in 2023[3]. - The healthcare business revenue reached approximately RMB 8,488.3 million, marking an 8.4% increase and accounting for 62.1% of total revenue[3]. - The total comprehensive income for the year was RMB 2,354.3 million, down from RMB 2,587.7 million in 2023[5]. - Basic earnings per share remained stable at RMB 1.07, while diluted earnings per share increased to RMB 1.02 from RMB 0.99 in 2023[4]. - The company's operating profit before tax for 2024 is RMB 2,907,119 thousand, an increase from RMB 2,866,213 thousand in 2023, reflecting a growth of approximately 1.1%[12]. - The company's pre-tax profit for 2024 was RMB 2,907,119,000, slightly up from RMB 2,866,213,000 in 2023, reflecting an increase of about 1.4%[67]. - The total revenue for the fiscal year ending December 31, 2024, was RMB 13,663,485 thousand, a slight increase from RMB 13,650,203 thousand in 2023, representing a growth of 0.1%[47]. Assets and Liabilities - The company's total assets as of December 31, 2024, were approximately RMB 86,032.3 million, up 7.1% from RMB 80,344.7 million in 2023[3]. - Non-current assets totaled approximately RMB 52,957.1 million, an increase from RMB 49,649.6 million in 2023[6]. - Current assets amounted to approximately RMB 33,075.2 million, compared to RMB 30,695.2 million in 2023[6]. - The company's total liabilities increased from RMB 29,903,345 thousand in 2023 to RMB 34,544,954 thousand in 2024, reflecting a rise of about 15.5%[7]. - The company's total equity increased from RMB 20,367,958 thousand in 2023 to RMB 22,869,745 thousand in 2024, a growth of around 12.3%[7]. - The company's total liabilities were reported at RMB 63,162,550 thousand, with financial liabilities at RMB 62,406,975 thousand and health liabilities at RMB 5,582,478 thousand[45]. - The total amount of bank and other financing secured by loans and receivables was RMB 9,227,529 thousand as of December 31, 2024, up from RMB 8,429,333 thousand in 2023[122]. Cash Flow - The cash flow from operating activities for 2024 is RMB 5,660,742 thousand, compared to RMB 6,041,080 thousand in 2023, indicating a decrease of about 6.3%[12]. - The company reported a net cash flow from operating activities of RMB 1,138,308 thousand for 2024, down from RMB 4,993,965 thousand in 2023, representing a significant decline of approximately 77.2%[13]. - Cash flow from financing activities showed a net outflow of RMB 520,670,000 in 2024, significantly improved from a net outflow of RMB 3,793,636,000 in 2023[14]. - The company's cash and cash equivalents decreased by RMB 467,325,000 in 2024, compared to an increase of RMB 141,332,000 in 2023[14]. - The cash and bank balances at the end of 2024 were RMB 3,168,050 thousand, down from RMB 3,395,033 thousand in 2023, a decrease of about 6.7%[107]. Revenue Segmentation - Medical service revenue accounted for RMB 7,295,603 thousand, contributing to the overall health business revenue of RMB 8,428,156 thousand[50]. - External customer revenue in the healthcare segment reached RMB 8,428,156 for 2024, compared to RMB 7,789,009 in 2023, reflecting a significant increase of 8.2%[51]. - The health technology business achieved a reportable revenue of RMB 697.0 million in 2024, representing a year-on-year growth of 189.9%[182]. - The financial business revenue decreased to RMB 5,227,167 thousand from RMB 5,882,032 thousand, indicating a decline of about 11.1%[162]. Expenses and Costs - The total cost of medical services was RMB 4,041,078 in 2024, slightly decreasing from RMB 4,077,373 in 2023, a reduction of 0.9%[60]. - The company reported a total of RMB 3,925,231 in employee benefits expenses for 2024, compared to RMB 3,348,351 in 2023, an increase of 17.2%[60]. - The total amount of other non-current assets increased to RMB 100,000 thousand in 2024 from RMB 25,941 thousand in 2023, reflecting a significant growth of approximately 285%[105]. Investments and Acquisitions - The company acquired 60% of Shandong Tuozhuang Medical Technology Co., Ltd. for RMB 82,500,000 on March 1, 2024[145]. - On May 1, 2024, the company purchased 70% of Beijing Zhongtaihe Medical Equipment Co., Ltd. for RMB 49,000,000[145]. - The total cash outflow for the acquisition, including cash paid, was RMB 332,496 thousand, resulting in a net cash outflow of RMB 239,147 thousand[148]. Strategic Initiatives - The group is focused on integrating into the national healthcare service system and improving service quality to meet the growing healthcare demands of the public[171]. - The company aims to enhance its integrated development system for ophthalmology, leveraging the capabilities of the newly acquired flagship hospital[177]. - The company plans to accelerate its transformation towards four key areas: healthcare, equipment manufacturing, chemical pharmaceuticals, and innovative businesses[191]. Regulatory and Compliance - The classification of liabilities as current or non-current has been clarified, with no impact on the group's financial position or performance following the application of the revisions[22]. - The group is evaluating the impact of the amendments to the Hong Kong Financial Reporting Standards, expecting no significant effect on consolidated financial data[22]. - The amendments to Hong Kong Financial Reporting Standard 9 clarify the derecognition date of financial assets or liabilities, with no expected significant impact on the group's financial statements[28].
环球医疗(02666) - 2024 - 年度业绩